Adding transcrocetin to standard therapy for glioblastoma
Part of Brain & nervous system, Cancer clinical trials.
This study tests whether adding an experimental drug called Liposomal Transcrocetin (L-TC) to standard radiation and temozolomide chemotherapy works better than standard treatment alone for people with newly diagnosed glioblastoma. The trial has two groups: one for younger patients who haven't had surgery, and one for older patients who may or may not have had surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed glioblastoma brain tumor.
- If you are 70 or younger, you need a biopsy but no surgery; if over 70, age alone is not a barrier if you are generally healthy.
- You must be able to have MRI scans and have acceptable blood counts and kidney/liver function.
- You cannot have had prior brain radiation or any other treatment for this tumor except surgery.
- You must not have serious ongoing diarrhea, digestive absorption problems, or another cancer within the last 5 years.
- You must be willing to use effective birth control and not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests whether adding a special type of radiofrequency electromagnetic field treatment to standard chemotherapy and radiation therapy helps people with newly diagnosed glioblastoma. It is for patients who are planning to receive standard treatment and have had surgery to remove the tumor.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This trial tests a combination of two experimental drugs, CTX-009 and CTX-471, for people whose glioblastoma has returned. The goal is to see if these drugs can help control the tumor.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.